Among bone tumours, Osteosarcoma (OS), Chondrosarcoma (CS) and Fibrosarcoma (FS) are highly metastatic with poor prognostic for survival. Standard procedures as surgery resection, radiotherapy and chemotherapy do not lead to full recovery or they do not affect metastasis [1-4]. Nowadays new molecular targets to cure cancer are during clinical trials. Clinical trials for OS are focused on using monoclonal antibody (dinutuximab) , immunotherapy (as using GM-CSF with influence on white blood cells)  or compounds acting as VEGFR inhibitor or PDGFR inhibitor - to reduce metastasis [7-9]. Clinical trials for CS are targeting the hedgehog pathway, focused on its inhibition , inhibition of IDH1/2 (common mutation in CS leading to hypermethylation)  or, as in OS treatment, inhibition of metastasis by acting on VEGFR . Beyond new chemotherapy and chemotherapy correlated with radiotherapy  clinical trials for FS are targeting gene fusion NTRK acting through inhibition of tropomyosin kinase receptor . This approach to treatment is a novelty on the global scale . Nitric oxide (NO) has many biological functions, e.g.: acting as neurotransmitter, reduced aggregation of platelets, acting as EDRF or reducing the oxidative stress in tumours [16-18]. Due to the dual nature of NO  anti-proliferative, pro-apoptotic and cell cycle arrest effect of NO were observed [20-25]. It could be a new area to find novel anti-cancer compound. One of the molecular targets under the scientists consideration is the activation of nitric oxide synthase (NOS). Górska-Ponikowska et al. [26-28] focused on experiments on OS 143B cells with 2-methoxyestradiol (2-ME) treatment, potentially novel compound playing the role of n-NOS activator. The researchers reported influence of 2-ME on down-regulation of mitochondrial biogenesis via direct influence on n-NOS level in OS 143B cells. What is more, L-lactate was indicated as potential molecular marker of anticancer therapy of tumours with metastasis.